Premium
O5‐06‐02: MULTI‐CENTER, RANDOMIZED, PLACEBO‐CONTROLLED, DOUBLE‐BLIND CLINICAL TRIAL OF ESCITALOPRAM ON THE PROGRESSION DELAYING EFFECT IN ALZHEIMER'S DISEASE: AN MRI STUDY FOR ATROPHY DELAYING EFFECT
Author(s) -
Choe Young Min,
Kim Ki Woong,
Jhoo Jin Hyeong,
Ryu SeungHo,
Choo IL Han,
Seo Eun Hyun,
Sohn Bo Kyung,
Park Jinsick,
Lee JongMin,
Yun Hyuk Jin,
Woo Jong Inn,
Lee Dong Young
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.04.507
Subject(s) - escitalopram , placebo , donepezil , dementia , psychology , medicine , antidepressant , oncology , psychiatry , hippocampus , disease , pathology , alternative medicine
Ab 1-42 (ng/L) Placebo 53 -6.3 (18.10) 39.8 p1⁄40.113 -12.4, 92.0 0.934 Rilapladib 48 33.6 (19.02) Ab 1-40 (ng/L) Placebo 53 -77.4 (181.33) -250.3 -772.9, 272.2 0.829 Rilapladib 48 -327.7 (190.56) Ab1-42/ Ab 1-40 Ratio Placebo 53 0.002 (0.0068) 0.016 -0.003, 0.036 Rilapladib 48 0.018 (0.0071) T-Tau (ng/L) Placebo 52 38.2 (29.98) -57.1 -144.5, 30.3 0.902 Rilapladib 46 -18.8 (31.90) P-tau (ng/L) Placebo 52 1.3 (1.67) -3.0 -7.9, 1.8 0.892 Rilapladib 47 -1.7 (1.76) AlbQ Placebo 46 0.11 (0.172) -0.24 -0.74, 0.26 0.828 Rilapladib 40 -0.13 (0.184) NF-L (ng/L) Placebo 52 191.2 (215.45) -256.6 -878.6, 365.4 0.792 Rilapladib 48 -65.4 (224.38)